ST段抬高型心肌梗死患者经皮冠状动脉介入治疗术后应用替格瑞洛与氯吡格雷的临床疗效观察  

Clinical observation of the efficacy of ticagrelor and clopidogrel in the treatment of patients with ST segment elevation myocardial infarction after percutaneous coronary intervention

作　　者：李辉[1] 闵静[2] 郭林[1] 

机构地区：[1]中国医科大学附属盛京医院第一心内科,沈阳110004 [2]中国医科大学附属第一医院ICU,沈阳110001

出　　处：《实用药物与临床》2017年第5期530-533,共4页Practical Pharmacy and Clinical Remedies

摘　　要：目的探索ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)术后应用替格瑞洛与氯吡格雷的临床疗效,为临床治疗STEMI提供依据。方法选择我院于2014年1月至2015年12月接受治疗的100例STEMI患者作为观察对象,按数字表法分为替格瑞洛组(观察组)和氯吡格雷组(对照组),每组50例,并对两组患者的临床疗效、并发症及心血管指标改善等情况进行分析。结果观察组治疗有效率明显高于对照组,差异有统计学意义(χ~2=3.961,P=0.017)。观察组并发症发生率明显低于对照组,差异有统计学意义(χ~2=4.192,P=0.002)。观察组心血管指标(左心室射血分数、左心室舒张末期半径、ST抬高段不良回落及血小板计数)改善疗效显著优于对照组,差异有统计学意义(t=4.644,P=0.016;t=3.502,P=0.023;χ~2=4.118,P=0.021;t=3.835,P=0.017)。结论应用替格瑞洛治疗STEMI具有较高的疗效,能增强抗血小板聚集,抗心绞痛,降低PCI术后并发症的发生率,具有较高的临床价值。Objective To explore the clinical efficacy of ticagrelor and clopidogrel in patients with ST seg- ment elevation myocardial infarction （STEMI）after percutaneous coronary intervention （PCI） , and to provide evidence for clinical treatment of STEMI. Methods A total of 100 cases of STEMI who were treated in our hospital from January 2014 to December 2015 were recruited as the study objects. The patients were divided into ticagrelor group （ observation group） and clopidogrel group （control group） according to the number table method,50 cases in each group. The indexes were analyzed mainly concerning the clinical curative effect, complications and the improvement of cardio- vascular indicators in the two groups. Results The treatment effective rate in observation group was significantly high- er than that in control group, and the difference was statistically significant （x^2 = 3. 961, P = 0. 017 ）. The total incidence of complications in observation group was obviously lower than that of control group after treatment, and the difference was statistically significant （x^2 = 4. 192 ,P = 0. 002 ）. The improvement of cardiovascular indicators （left ventricular e- jection fraction, the left ventricular end-diastolic radius, the bad back of ST elevation period and platelet count） in ob- servation group were obviously better than those in control group after treatment, and the differences were statistically significant （t=4.644,P=0. 016;t=3.502,P=0. 023;X2 =4. 118,P=0. 021;t=3.835,P=0. 017）.Conclusion Ti- cagrelor in the treatment of STEMI has high efficacy, and can enhance the effect of anti-platelet aggregation and antiangina, and reduce the incidence of postoperative complications of PCI, so it has high clinical value.

关 键 词：STEMI PCI 替格瑞洛 氯吡格雷 

分 类 号：R542.22[医药卫生—心血管疾病]